Compare Mongodb Inc (MDB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Mesoblast Limited — how do they compare? Mongodb Inc trades at $372.99 (market cap $29.24B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mongodb Inc is far larger — about 16.7× Mesoblast Limited's market cap, and Mongodb Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Mesoblast Limited for 14 Days on average.
| MDB | MESO | |
|---|---|---|
Market Cap | $29.24B | $1.75B |
Volume | 1,304,995 | 239,027 |
Sector | Technology | Health |
52-Week High | $472.29 | $20.96 |
52-Week Low | $225.95 | $13.19 |
Typical Hold Time | 45 Days | 14 Days |
Enterprise Value | $26.86B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $363.03, up 0.64% today, with a bearish technical signal despite recent positive earnings beats. The company reported strong revenue growth, reaching $2.01 billion in 2025, but remains unprofitable with a net loss of $129.07 million. Recent news highlights AI product launches and a CEO transition, with analysts maintaining a bullish consensus price target of $456.76.
The outlook is mixed: strong revenue growth and AI initiatives offer upside, but high valuation ratios and persistent losses pose risks. Investor sentiment is cautiously optimistic, though technical indicators suggest near-term pressure. Key risks include execution challenges and competitive threats in the database market.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
